Cancer stem cells are like zombies—even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers ...
Jun 9, 2016
0
125
For Kristin Kleinhofer, two words—"choose hope"—have been a lifeline.
Apr 27, 2016
0
2
According to a popular saying, 'timing is everything.' For acute myeloid leukemia (AML), that adage may be true. In a paper published in the April 7 issue of Cell, an international team led by researchers from the Broad Institute ...
Apr 8, 2016
1
77
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered that a protein produced by a cancer gene leads to the development of a deadly, late-stage form of prostate ...
Apr 1, 2016
0
6
A study of gene expression in leukemia cells has identified an RNA binding protein that plays an important role in driving the development of cancer. The protein is normally active in fetal tissue and switched off in adults, ...
Mar 14, 2016
0
39
ONC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantel cell lymphoma (MCL) and acute myeloid leukemia (AML), according to a recent ...
Feb 16, 2016
0
3
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today—an inability to get patients off treatment.
Feb 16, 2016
1
58
(HealthDay)—Antibody therapy before stem cell transplant may benefit patients with acute leukemia, according to research published in the Jan. 7 issue of the New England Journal of Medicine.
Jan 7, 2016
0
0
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 ...
Dec 21, 2015
0
4
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber ...
Dec 7, 2015
0
0
